AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
TLC G-65 Phase III trials started in Europe. (new drug for Mycobacterium avium-intracellulare infection) (United Kingdom)
United Kingdom
TLC G-65, a new drug for the most common systemic bacterial infection afflicting AIDS patients, Mycobacterium avium-intracellulare (MAI), has entered a Phase III clinical trial in Europe, the Liposome Company Inc., Princeton, New Jersey, announced.
The MAI study was initiated at St. Stephen's Hospital, London, England, one of the most prestigious AIDS therapy centers in the United Kingdom. It is led by principal investigator Dr. Brian Gazzard. At least one additional study location will be added shortly.
TLC G-65, a proprietary drug of the Liposome Company, is a liposomal aminoglycoside antibiotic that has previously been shown in …
-
- OXiGENE receives regulatory clearance to commence Phase III clinical trial...
-
News wire article from: Europe Intelligence Wire
December 12, 2005
700+ words
-
- First patient in Phase III clinical trial of Doxil in Kaposi's sarcoma...
-
Newspaper article from: AIDS Weekly
February 1, 1993
700+ words
-
- Basilea Pharmaceutica opens U.S. phase III study on alitretinoin for the...
-
News wire article from: Europe Intelligence Wire
December 17, 2008
700+ words
-
- Pharmexa goes to phase III.
-
News wire article from: Europe Intelligence Wire
April 26, 2006
700+ words
-
- Basilea's antifungal isavuconazole passed phase III clinical trial futility...
-
News wire article from: Europe Intelligence Wire
January 29, 2010
700+ words
